KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Idexx Laboratories (IDXX) over the last 16 years, with Dec 2024 value amounting to $288.3 million.

  • Idexx Laboratories' Cash & Equivalents fell 32.55% to $208.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $208.2 million, marking a year-over-year decrease of 32.55%. This contributed to the annual value of $288.3 million for FY2024, which is 36.50% down from last year.
  • As of FY2024, Idexx Laboratories' Cash & Equivalents stood at $288.3 million, which was down 36.50% from $453.9 million recorded in FY2023.
  • Over the past 5 years, Idexx Laboratories' Cash & Equivalents peaked at $453.9 million during FY2023, and registered a low of $112.5 million during FY2022.
  • Its 3-year average for Cash & Equivalents is $284.9 million, with a median of $288.3 million in 2024.
  • Per our database at Business Quant, Idexx Laboratories' Cash & Equivalents spiked by 325.05% in 2020 and then tumbled by 62.37% in 2021.
  • Over the past 5 years, Idexx Laboratories' Cash & Equivalents (Yearly) stood at $383.9 million in 2020, then crashed by 62.37% to $144.5 million in 2021, then decreased by 22.09% to $112.5 million in 2022, then surged by 303.33% to $453.9 million in 2023, then slumped by 36.50% to $288.3 million in 2024.